Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) – Pipeline Review, H2 2016’, provides in depth analysis on Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) targeted pipeline therapeutics.

The report provides comprehensive information on the Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2)

The report reviews Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) targeted therapeutics and enlists all their major and minor projects

The report assesses Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Alkermes Plc

Biomar Microbial Technologies

Cyxone AB

OncBioMune Pharmaceuticals Inc.

Transgene SA

ZIOPHARM Oncology, Inc.

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) Overview 7

Therapeutics Development 8

Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) - Products under Development by Stage of Development 8

Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) - Products under Development by Therapy Area 9

Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) - Products under Development by Indication 10

Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) - Pipeline Products Glance 11

Late Stage Products 11

Early Stage Products 12

Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) - Products under Development by Companies 13

Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) - Products under Development by Universities/Institutes 15

Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) - Therapeutics Assessment 17

Assessment by Monotherapy/Combination Products 17

Assessment by Mechanism of Action 18

Assessment by Route of Administration 20

Assessment by Molecule Type 22

Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) - Companies Involved in Therapeutics Development 24

Alkermes Plc 24

Biomar Microbial Technologies 25

Cyxone AB 26

OncBioMune Pharmaceuticals Inc. 27

Transgene SA 28

ZIOPHARM Oncology, Inc. 29

Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) - Drug Profiles 30

ALKS-4230 - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

Anti-PD1 Antibody + TILT-123 - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

Biologic to Activate IL-2 for Graft Versus Host Disease - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

BNZ-1 - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

Chimeric Antigen Receptor T Cell + TILT-123 - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

IB-08C175 - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

Prostatac - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

T-20K - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

TG-4010 - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

TILT-123 + Tumor Infiltrating Lymphocytes - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

Vaccine to Target CD80 and IL-2 for Acute Myeloblastic Leukemia - Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

Vaccine to Target IL-2 and E7 Protein for Cervical Cancer and Oropharyngeal Cancer - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) - Dormant Projects 47

Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) - Discontinued Products 50

Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) - Featured News & Press Releases 51

Oct 24, 2016: Immunotherapy Expert Dr. Brian Barnett Joins OncBioMune Scientific Advisory Board 51

Oct 19, 2016: OncBioMune Receives Notice of Patent Allowance for Novel Cancer Vaccine ProscaVax in Mexico 51

Sep 26, 2016: OncBioMune CEO Dr. Jonathan Head to Present Abstract on Prostate Cancer Vaccine at Second CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science Into Survival 52

Aug 08, 2016: Latest Data From Phase 1 Trial of ProscaVax for Prostate Cancer Reinforces Safety and Benefit of Novel Cancer Vaccine 52

Jul 20, 2016: Pre-Clinical Research Supports Additional Studies of OncBioMune Technology for Breast Cancer Vaccine 53

Jul 13, 2016: OncBioMune Submits Protocol to Initiate Phase 2/3 Trial of ProscaVax for Prostate Cancer 54

Jun 14, 2016: OncBioMune Provides Corporate Update; ASCO Reinforces Market Opportunity for New Prostate Cancer Vaccine as Phase 2 Trial Approaches 54

Jun 02, 2016: Mexican Regulatory Authorities Supportive of OncBioMunes Phase 2 of ProscaVax for Prostate Cancer 56

May 25, 2016: Alkermes Announces Initiation of Phase 1 Clinical Study of Immuno-Oncology Drug Candidate ALKS 4230 57

May 18, 2016: Doctors Voice Optimism About Phase 2 Trial of ProscaVax in Mexico for Prostate Cancer 57

May 11, 2016: OncBioMune Provides Update on Phase 2 Clinical Trials of ProscaVax for Prostate Cancer 58

May 04, 2016: OncBioMune Submits Protocol to Principal Investigators for Two Phase 2 Clinical Trials of ProscaVax for Prostate Cancer 59

Apr 28, 2016: OncBioMune Receives Notice of Patent Allowance for Cancer Vaccine ProscaVax in China 60

Apr 12, 2016: OncBioMune Receives Notice of Patent Allowance for Cancer Vaccine ProscaVax in Hong Kong 61

Mar 29, 2016: Multiple sclerosis: plant peptide could prevent onset of the disease 61

Appendix 63

Methodology 63

Coverage 63

Secondary Research 63

Primary Research 63

Expert Panel Validation 63

Contact Us 63

Disclaimer 64

List of Tables

List of Tables

Number of Products under Development for, H2 2016 8

Number of Products under Development by Therapy Area, H2 2016 9

Number of Products under Development by Indication, H2 2016 10

Comparative Analysis by Late Stage Development, H2 2016 11

Comparative Analysis by Early Stage Products, H2 2016 12

Number of Products under Development by Companies, H2 2016 13

Products under Development by Companies, H2 2016 14

Number of Products under Investigation by Universities/Institutes, H2 2016 15

Products under Investigation by Universities/Institutes, H2 2016 16

Assessment by Monotherapy/Combination Products, H2 2016 17

Number of Products by Stage and Mechanism of Action, H2 2016 19

Number of Products by Stage and Route of Administration, H2 2016 21

Number of Products by Stage and Molecule Type, H2 2016 23

Pipeline by Alkermes Plc, H2 2016 24

Pipeline by Biomar Microbial Technologies, H2 2016 25

Pipeline by Cyxone AB, H2 2016 26

Pipeline by OncBioMune Pharmaceuticals Inc., H2 2016 27

Pipeline by Transgene SA, H2 2016 28

Pipeline by ZIOPHARM Oncology, Inc., H2 2016 29

Dormant Projects, H2 2016 47

Dormant Projects (Contd..1), H2 2016 48

Dormant Projects (Contd..2), H2 2016 49

Discontinued Products, H2 2016 50

List of Figures

List of Figures

Number of Products under Development for, H2 2016 8

Number of Products under Development by Therapy Area, H2 2016 9

Number of Products under Development by Top 10 Indication, H2 2016 10

Comparative Analysis by Late Stage Development, H2 2016 11

Comparative Analysis by Early Stage Products, H2 2016 12

Assessment by Monotherapy/Combination Products, H2 2016 17

Number of Products by Mechanism of Actions, H2 2016 18

Number of Products by Stage and Mechanism of Actions, H2 2016 18

Number of Products by Routes of Administration, H2 2016 20

Number of Products by Stage and Routes of Administration, H2 2016 20

Number of Products by Molecule Types, H2 2016 22

Number of Products by Stage and Molecule Type, H2 2016 22

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports